World Orphan Drug Congress

Venue: Crown Plaza

Location: Geneva, Switzerland

Event Date/Time: Nov 29, 2010 End Date/Time: Dec 01, 2010
Registration Date: Nov 29, 2010
Early Registration Date: Sep 10, 2010
Report as Spam


World Orphan Drug Congress
29 November - 1 December 2010
Crowne Plaza, Geneva, Switzerland

Strategy, partnerships and opportunity for Pharma, Biotech and Investors

The World Orphan Drug Congress is the World’s first industry-led conference tackling global trends, market access and Big Pharma impact in rare diseases.

By attending you will learn about strategy, innovation and the future of the orphan drugs industry. From global trends and orphan drug success stories to crucial partnerships and commercial strategies, the World Orphan Drugs Congress is the only executive-level industry meeting place for new ideas in the rare disease space.

2010 key speakers include:

* Dr Ulf Wiinberg, Chief Executive Officer, Lundbeck
* Hans Schikan, Chief Executive Officer, Prosensa
* Dr Martin Nicklasson, Chief Executive Officer, Swedish Orphan Biovitrum
* Dr Yann Le Cam, Chief Executive Officer, EURORDIS
* Marc Dunoyer, Head of the Rare Disease Business Unit, GlaxoSmithKline
* Jean-Jacques Bienaime, Chief Executive Officer, BioMarin
* Dr David Aviezer, Chief Executive Officer, Protalix
* Damian Marron, Chief Executive Officer, Trophos
* Peter Saltonstall, Chief Executive Officer, NORD
* Dr Ed Mascioli, Head of the Rare Disease Research Unit, Pfizer

Congress highlights

Hear from Pfizer, GSK and Eli Lilly on Big Pharma entry to the rare disease space. How to move away from reliance on blockbuster products towards specialist indications driving novel revenues

Find out how Lundbeck and BioMarin are formulating biotech commercial strategies to drive orphan drug business models. Develop strategies to maximise revenues from orphan drugs through gaining market access and broadening the product label

Learn from PTC Therapeutics and Trophos on improving clinical development of orphan drugs. How to design and adapt clinical trials to save time and money and making the most of development incentives

Understand how Genzyme, Prosensa and Shire HGT are utilising patient partnerships to drive development and commercialisation. Using patient partnerships and registries to maximise market outcomes for orphan drugs

Hear orphan drug success stories from Protalix, Swedish Orphan Biovitrum and Alexion Pharmaceuticals. And apply their lessons learned to your own development strategies

Understand product indication expansion and multiple orphan designations with Novartis Oncology. How developing orphan drugs for key indications present opportunities to gain access to further orphan indications with similar disease mechanisms

Find out how rare disease pioneers throughout the industry are tackling orphan drug access and market authorisation challenges. And lever their expertise to understand what is critical for successful product approval

Discuss orphan product reimbursement with government stakeholders and industry thought-leaders from Actelion and Shire. Contribute to government-level strategies being developed to ensure sustainable market access and acceptable pricing for orphan drugs

Please visit the website for full programme and speaker details.


Paul Gilbertson
Senior Marketing Manager
Terrapinn Ltd
tel: +44 (0)20 7092 1245
fax: +44 (0)20 7242 1508